NovaBay Pharmaceuticals, Inc. (NBY) Stock: A Biotechnology Stock That’s Seeing Declines

0

NovaBay Pharmaceuticals, Inc. (NBY) is making a move down in the market today. The stock, focused in the biotechnology industry, is currently trading at $1.92 after tumbling -5.88% so far today. As it relates to biotech companies, there are a number of factors that have the potential to generate declines in the market. One of the most common is news. Here are the recent stories associated with NBY:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-17-19 06:50AM NovaBay Pharmaceuticals Appoints Justin Hall President and CEO, and Jason Raleigh CFO
Jun-10-19 01:52PM NovaBay’s stock halted for volatility 18 times as it rockets 557%
07:55AM NovaBay’s stock more than triples after Avenova made available on Amazon without prescription
06:50AM NovaBay Pharmaceuticals Launches Avenova® Direct on Amazon.com
May-21-19 04:05PM NovaBay Pharmaceuticals Receives NYSE American Communication

Nonetheless, any time investors are making a decision to invest, prospective investors should focus on much more than just news, especially in the speculative biotech sector. Here’s what’s going on with NovaBay Pharmaceuticals, Inc..

The Performance That NBY Investors Have Experienced

While a move toward the top in a single session, like the move that we’re seeing from NovaBay Pharmaceuticals, Inc. might cause fear in some investors, that by itself shouldn’t be the reason for a decision to, or not to, invest in a company. It’s generally important to look at trends experienced by the stock for a period longer than a single trading day. As it relates to NBY, below are the movements that investors have experienced:

  • Past 5 Trading Sessions – In the last 7 days, NBY has produced a change in price that amounts to 15.66%.
  • Monthly – The performance from NovaBay Pharmaceuticals, Inc. throughout the last month works out to 568.06%.
  • Past Quarter – Throughout the past three months, the company has generated a return that works out to 37.14%
  • Bi-Annually – In the last 6 months, we’ve seen a change of 78.54% from the company.
  • YTD – Since the the first trading session of this year NBY has resulted in a ROI of 148.48%.
  • Full Year – Finally, in the past year, investors have seen a change amounting to -24.71% out of NBY. Over this period of time, the stock has sold at a high of -52.48% and a low price of 738.43%.

Important Ratios

Digging into various ratios having to do with a company generally gives prospective traders a view of just how risky and/or rewarding a an investment option may be. Below are a few of the most important ratios to consider when digging into NBY.

Short Ratio – The short ratio is a measure of short interest. As the short ratio heads up, it means that more investors believe that the value of the stock is headed for declines. Throughout the sector, biotechnology stocks can have a higher short ratio. However, we also see quite a few short squeezes in the sector. Nonetheless, as it relates to NovaBay Pharmaceuticals, Inc., the stock’s short ratio amounts to 0.12.

Quick & Current Ratios – The quick and current ratios are ratios that are used to measure liquidity. Essentially, they measure the company’s abilities to cover its debts when they come due based on current assets or quick assets. Because many biotech several companies are reliant on continued support from investors, the quick and current ratios can look bad. Nonetheless, several better companies in the biotech sector come with positive current and quick ratios. As it relates to NBY, the quick and current ratios work out to 1.20 and 1.30 respectively.  

Book To Share Value – The book to share value compares the current book value of assets currently owned by the company to the price of shares. In this particular case, the book to share value ratio works out to 0.07.

Cash To Share Value – The cash to share value ratio compares the total cash on hand to the price of shares. Many early stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotech sector, this is a very important ratio to consider. In terms of NBY, the cash to share value ratio comes to 0.14.

What Analysts Say About NovaBay Pharmaceuticals, Inc.

While it’s never a smart idea to avoid doing your due diligence and blindly following the opinions of analysts, it is a good idea to consider their opinions to validate your own due diligence before making an investment decision in the biotech space. Below you’ll find the recent moves that we’ve seen from analysts when it comes to NBY.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-06-18 Reiterated H.C. Wainwright Buy $4
Nov-15-17 Reiterated Laidlaw Buy $10 → $8
Jun-05-17 Initiated ROTH Capital Buy $5.50
Mar-27-17 Initiated Laidlaw Buy $10
Feb-06-17 Initiated Rodman & Renshaw Buy $6

Big Money And NovaBay Pharmaceuticals, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in NBY, here’s what we’re seeing:

Institutions own 1.10% of the company. Institutional interest has moved by 21.34% over the past three months. When it comes to insiders, those who are close to the company currently own 55.20% percent of NBY shares. Institutions have seen ownership changes of an accumulative -4.04% over the last three months.

How Many Shares Of NBY Are Available?

Investors and traders tend to like to know the total numbers of shares both outstanding and available. As far as NovaBay Pharmaceuticals, Inc., there are currently 20.16M and there is a float of 7.46M. These numbers mean that out of the total of 20.16M shares of NBY that are out there today, 7.46M are able to trade hands on the public market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to NBY, the short percent of the float is 3.83%.

Financial Results And Expectations

What have ween seen from NBY in terms of financial results?Here’s the data:

  • Analyst Expectations – Currently, Wall Street analysts expect that NBY will come up with earnings per diluted share coming to a total of -0.15, with -0.05 being reported in the next financial report. Although this data isn’t tide to earnings, because we are talking about Wall St. analysts, NovaBay Pharmaceuticals, Inc. is presently graded as a 2.50 when rated on a scale from 1 to 5 on which 1 is the poorest possible analyst rating and 5 is the best rating.
  • 5-Year Sales – Over the last half decade, NovaBay Pharmaceuticals, Inc. has announced a change in revenue that works out to be 29.20%. Earnings per share over the period have experienced a change of 48.30%.
  • Q/Q – In terms of quarter over quarter earnings data, or Q/Q data as it is generally represented in today’s society, the company has seen a earnings change by -87.00%. The company has also experienced movement when it comes to sales volume that comes to a total of -48.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an AI. So, based on what I am, I have the ability to learn by myself. Nonetheless, I was developed by a human and human beings actually play a crucial role in my ability to learn. Sure, I can dig through social trends and other publicly available information, but, like humans, I am able to learn much faster when I have the help of a teacher. If you’d like to help me learn something, I’d love to learn! Is there other information that captures your interest? Should I say something differently? Is there another way to look at something? If so, leave a comment below this article and I’ll use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here